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Introduction: Nicotine dependence is a chronic disorder often characterized by multiple failed 
quit attempts (QAs). Yet, little is known about the sequence of methods used across multiple 
QAs or how this may impact future ability to abstain from smoking. This prospective cohort 
study examines the effectiveness of switching smoking-cessation medications (SCMs) across 
multiple QAs. 
Methods: Adult smokers (aged ≥18 years) participating in International Tobacco Control 
surveys in the United Kingdom, U.S., Canada, and Australia (N=795) who: (1) completed two 
consecutive surveys between 2006 and 2011; (2) initiated a QA at least 1 month before each 
survey; and (3) provided data for the primary predictor (SCM use during most recent QA), 
outcome (1-month point prevalence abstinence), and relevant covariates. Analyses were 
conducted in 2016. 
Results: Five SCM user classifications were identified: (1) non-users (43.5%); (2) early users 
(SCM used for initial, but not subsequent QA; 11.4%); (3) later users (SCM used for subsequent, 
but not initial QA; 18.4%); (4) repeaters (same SCM used for both QAs; 10.7%); and (5) 
switchers (different SCM used for each QA; 14.2%). Abstinence rates were lower for non-users 
(15.9%, OR=0.48, p=0.002), early users (16.6%, OR=0.27, p=0.03), and repeaters (12.4%, 
OR=0.36, p=0.004) relative to switchers (28.5%). 
Conclusions: Findings suggest smokers will be more successful if they use an SCM in QAs and 
vary the SCM they use across time. That smokers can increase their odds of quitting by 
switching SCMs is an important message that could be communicated to smokers. 
  
3 
INTRODUCTION 
Nicotine dependence is a chronic relapsing disorder often characterized by multiple failed quit 
attempts (QAs),1 which calls for a chronic disease management approach.2 Motivation to quit is 
an established predictor of making a future QA, but it does not predict sustained abstinence.3 
Thus, even among smokers motivated to quit, most QAs will result in relapse, and most smokers 
will need to be recycled to another QA. Fortunately, many smokers remain interested in quitting, 
even after a failed QA. For example, within a sample of smokers who reported making a failed 
QA, 78% were interested in making another QA within 1 month.4 Indeed, evidence indicates the 
vast majority of smokers are frequently thinking about and making efforts to stop smoking.5 
 
Although most former and current smokers report making multiple QAs during their lifetime,6,7 
little is known about how methods of quitting vary across attempts, and whether consistency or 
inconsistency of quit method increases the likelihood of maintaining abstinence over an extended 
time period. Most QAs are unassisted, that is, without use of any smoking-cessation medications 
(SCMs) or behavioral treatments, despite strong evidence that both enhance long-term quitting 
success.8,9 Observational, prospective cohort studies have characterized frequency of QAs,7,10 
prevalence with which SCMs are used, and the effectiveness of SCMs.8,11,12 However, little is 
known about the sequence of quit methods smokers might use across multiple QAs. One study 
suggests those making a QA in the past year were significantly more likely to try again within 6 
months, irrespective of whether they had used a SCM or not, compared with those who had not 
made a QA in the past year; smokers were also more likely to try the same quit method used on a 
previous QA within the past 6 months, but this study did not evaluate quit success.13 On one 
hand, consistency of quit method might improve quitting success, if only because the smoker is 
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already familiar with the method and presumably knows how to improve upon it (e.g., not make 
the same mistakes twice). On the other hand, changing the method across QAs might lead to 
improved quitting by allowing the smoker to try something new with the hope of achieving a 
different outcome. Complicating this issue is that a smoker might change from using an 
evidence-based method to one that is not evidence based (e.g., hypnotherapy), or vice versa, and 
thus evaluation of quitting success may be attributable to the potency of the quit method used 
rather than the effect of trying something new. For this reason, analysis in this paper is limited to 
switching between roughly comparable evidence-based SCMs. 
 
There are few naturalistic evaluations of consistency of SCMs over successive quit attempts, 
though several RCTs have examined the more general concept of treatment recycling. One study 
found no benefit of nicotine patch among smokers who initially tried, and failed, and tried again 
with either patch or nasal spray,14,15 though another study found success for repeated treatment 
with patch plus behavioral counseling.16 Nicotine lozenge improved cessation rates among 
smokers who had a treatment history with nicotine patch, gum, inhaler, or bupropion.17 Other 
studies have shown benefits of retreatment with varenicline18 and bupropion,19 the latter being 
equally efficacious for relapsers who did or did not have a history of nicotine-replacement 
therapy (NRT) use.20 Thus, clinical trial evidence is mixed with regard to efficacy of switching 
versus using the same quit method. 
 
Several treatment algorithms exist to aid clinicians,21–24 and public health agencies have related 
treatment recommendations. The most recent expert treatment algorithm suggests prescription of 
a new SCM or trial of the same SCM at a higher dose.21 Unfortunately, the evidence to support a 
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recommendation that patients who quit and relapse should switch or try the same SCM on a 
subsequent quit attempt is scant. The current study was undertaken to help fill this gap. 
 
In this study, the effectiveness of consistency/variability of SCMs across multiple QAs is 
examined using data from an international cohort study of adult smokers. Specifically, analyses 
characterize the prevalence of switching or using the same SCM within approximately 1 year of 
initial relapse. Relapsers who on a subsequent QA use an SCM (or combination) different from 
that used during a recent QA are herein referred to as switchers, and those who use the same 
SCM (or combination) across two QAs are denoted as repeaters. This prospective cohort study 
tests the hypothesis that switchers will have greater quit success. 
 
METHODS 
Study Population 
Participants were adult smokers (aged ≥18 years) in the International Tobacco Control Four 
Country Survey. Nationally representative samples from the United Kingdom (UK), Canada, 
Australia, and U.S. completed standardized telephone interviews annually since 2002 as part of 
an ongoing prospective cohort study.25 
 
Analyses are restricted to data collected between 2006 and 2011 (Waves 5–8), allowing for 
equivalent response options for SCMs (i.e., varenicline first available in 2006) and consistency in 
SCM questions (i.e., assessed differently at other waves). Participants reported the number of 
QAs made over the past year, duration of most recent QA, and use of SCMs during the most 
recent QA. Of the 8,245 participants in the Wave 5 assessment (considered baseline herein), 
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those with a QA that started within 1 month of subsequent assessments (n=24) were excluded 
because the primary outcome was 1-month point prevalence abstinence at follow-ups. Inclusion 
criteria were:  
1. reported QAs on two consecutive waves; 
2. and provided valid data for all predictors, smoking status, and control variables.  
QAs could have occurred in the time leading up to Waves 6 and 7 (Wave Pair 1, 59%), or Waves 
7 and 8 (Wave Pair 2, 41%). The final sample included 1,057 wave pairs that comprised 795 
respondents, such that respondents could contribute to a single wave pair (67%) or both (33%). 
 
Measures 
At each wave, participants were coded as abstinent when no smoking was indicated within the 
past month (i.e., ≥1-month point prevalence abstinence). 
 
Smoking-cessation medication use. At each wave, those who made a QA since the last wave 
were asked which of the following SCMs they used to aid their most recent QA: nicotine gum, 
nicotine patch, nicotine lozenge, nicotine tab, other NRT, bupropion, varenicline, and other 
prescription (options were not mutually exclusive). Based on the two consecutive QAs assessed 
participants could fall into one of these SCM use groups:  
1. non-users: no SCM used across both QAs; 
2. early users: SCM used for initial, but not subsequent QA; 
3. later users: SCM used for subsequent, but not initial QA; 
4. repeaters: same SCM (or combination) used for both QAs; or 
5. switchers: different SCM (or combination) used for each QA.  
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When more than one SCM (i.e., combination) was used for both QAs, repeaters were defined as 
those who used the exact same combination of SCMs across both QAs (e.g., gum and patch), 
whereas switchers used a different combination for each QA (e.g., gum and patch, then lozenge 
and patch). Those who used SCMs at both QAs but increased or decreased the number of SCMs 
used were considered switchers (e.g., gum and patch, then gum). 
 
To replicate analyses conducted in a prior International Tobacco Control Four Country Survey 
study on the effectiveness of SCMs,8 the following baseline variables were included:  
1. country; 
2. sex; 
3. ethnicity/racial group (majority or minority, based on racial/ethnic group in the UK, 
Canada, and U.S., and English language spoken at home in Australia); 
4. age group (18–24, 25–39, 40–54, or ≥55 years); 
5. level of education (low, moderate, or high; “low” defined as completion of high school or 
less in Canada, U.S., and Australia, or secondary/vocational or less in the UK, 
“moderate” as completion of community college/trade/technical school/some university 
(no degree) in Canada and the U.S., college/university (no degree) in the UK, or 
technical/trade/some university (no degree) in Australia, and “high” if respondent 
completed university or postgraduate in all countries); 
6. annual household income (low, moderate, high, or unknown; “low” coded if income was 
<$30,000 in the U.S., Canada, and Australia or <£30,000 in the UK, “moderate” if it was 
between $30,000 and $59,999 or £30,000 and £44,999, and “high” if it was ≥$60,000 or 
£45,000; 
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7. nicotine dependence, as measured by the heaviness of smoking index26; and 
8. self-efficacy, as assessed with the item: If you decided to give up smoking completely in 
the next 6 months, how sure are you that you would succeed?, with participants classified 
as low, moderate, or high (“low” defined as those who responded not at all sure or 
slightly sure, “moderate” as those who indicated moderately sure, and “high” were those 
that reported very sure or extremely sure). 
 
The study protocol was approved by the IRBs or research ethics boards of the University of 
Waterloo, Roswell Park Cancer Institute, Medical University of South Carolina, University of 
Strathclyde, University of Stirling, The Open University, and The Cancer Council Victoria. 
 
Statistical Analysis 
Analyses were conducted in 2016 with SPSS, version 23, and significance indicated by α<0.05 
(two-tailed). One-way ANOVAs for continuous variables and chi-square analyses for categorical 
variables were used to explore differences across the five SCM use groups in baseline 
demographic and smoking-related characteristics. Multi-predictor generalized estimating 
equations analyses tested demographic and smoking-related characteristics as predictors of SCM 
use group membership with the following comparisons: repeaters versus all other groups, 
switchers versus all other groups, and repeaters versus switchers. Generalized estimating 
equations analyses were used to examine the relationship between SCM use and 1-month point 
prevalence abstinence. Specifically, repeated longitudinal logistic regression analyses were 
conducted with specifications for binomial distributions and unstructured within-person 
correlation matrixes. Analyses allowed participants to contribute to multiple wave pairs, while 
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controlling for correlations between responses. Unadjusted and adjusted analyses showed the 
same pattern of results, and adjusted results are reported. 
 
RESULTS 
Table 1 depicts sample characteristics. Almost half of the sample (45.3%) were non-users, 11.4% 
were early users, 18.4% were later users, 10.7% were repeaters, and 14.2% were switchers. 
When comparing repeaters or switchers with other SCM use groups, elevated nicotine 
dependence was associated with a greater likelihood of being a repeater (OR=1.2, p=0.02) and a 
switcher (OR=1.3, p<0.001). Country-level associations were also found, such that relative to 
U.S. respondents, those in Australia were more likely to be repeaters (OR=2.4, p=0.005) and 
those in the UK were less likely to be switchers (OR=0.5, p=0.02). No differences emerged 
between switchers and repeaters across any baseline characteristics. 
 
As depicted in Table 2, the highest quit rates were observed for switchers. Switchers were the 
only group significantly different from non-users, being over twice as likely to achieve 1-month 
point prevalence abstinence. Only repeaters had lower quit rates than non-users, although this 
was not statistically significant. To allow for comparison of repeaters versus switchers directly, 
the same analyses were rerun with the switchers as the ref group. Repeaters were less likely to 
achieve 1-month point prevalence abstinence. The same pattern was true for early users, whereas 
no significant difference was observed for later users. 
 
To explore if better quit rates for switchers may be accounted for by SCM selection, specific 
SCMs used by repeaters and switchers were examined (Table 3). Patch only and varenicline only 
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were the most commonly used SCMs for repeaters. Relative to repeaters, switchers had 
comparable rates of patch-only use at the initial QA and comparable rates of varenicline-only use 
at the subsequent QA. Switchers also showed a shift away from bupropion only, gum only, and 
concurrent use of patch and gum. Each of the remaining specific SCMs were used by very few 
participants so data were collapsed across SCM combinations to determine rates at which any 
NRT, NRT combo, bupropion, varenicline, and prescription SCM (i.e., bupropion, varenicline, 
prescription NRT, or other prescription) were used. At the subsequent QA, switchers had lower 
rates of any NRT use compared with repeaters (–7.0%), but higher rates for NRT combination 
(+10.0%), bupropion (+4.2%), varenicline (+12.3%), and any prescription SCM (+9.8%). 
Abstinence outcomes were still significantly better for switchers, relative to repeaters, in 
generalized estimating equations models that controlled for use of each of the cumulative SCM 
variables at the subsequent QA (ps<0.02). 
 
Overall, there was greater heterogeneity in combinations of SCMs used by switchers. Switchers 
used 20 different SCM combinations during the initial QA and 33 during the subsequent QA, 
whereas only 15 were used among repeaters. Repeaters used a single SCM for 89.4% of their 
QAs, and two SCMs for the remaining 10.6%. Among switchers, initial QAs were aided by a 
single SCM the majority of the time (78.7%), but two SCMs were used on a considerable portion 
(20.0%), and a small portion used three or four SCMs (0.7% each). On the subsequent QA, a 
smaller subset of switchers used a single SCM (68.7%), and higher rates were observed for the 
use of two (24.7%), three (4.7%), or four (2.0%) SCMs. Thus, switchers showed a trend toward 
use of more SCMs on any given QA, a pattern that was even more pronounced during the 
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subsequent QA. Switchers still had significantly better abstinence outcomes than repeaters 
(p=0.002) when number of SCMs used at the subsequent QA was controlled for. 
 
DISCUSSION 
This study examined variability in SCMs used across two QAs, and its impact on cessation 
outcomes. Smokers were more likely to succeed in quitting when they used a different SCM after 
a failed attempt than smokers who tried again to quit using the same SCM. Findings parallel 
prior population-based studies that show most smokers make QAs in the absence of any SCM. 
However, the current data show a considerable subset of smokers report use of evidence-based 
SCMs after a failed QA, and this is beneficial for quitting success. No differences were found 
between repeaters and switchers on baseline demographic and smoking-related variables, 
although both groups were more nicotine dependent than smokers who used SCMs on only one 
QA (early/later users) or not at all (non-users). Overall, results suggest smokers could be advised 
try a new SCM (or combination thereof) upon making a new QA. 
 
Findings raise the question of why switching SCMs may improve cessation outcomes. Type and 
number of SCMs were explored as potential explanations. Repeaters primarily used only one 
SCM, whereas switchers were shifting toward the use of more than one SCM on a given QA. For 
example, rates of any use of varenicline (i.e., with or without additional SCM) were higher for 
switchers than repeaters at the subsequent QA. Switchers also were more likely to use any 
prescription SCM at the subsequent QA, which provides the advantage of interaction with a 
health professional who may provide counseling. Despite differences in the number or type of 
SCMs used at the subsequent QA, controlling for these variables statistically did not suppress the 
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effects of switching on quit success. Thus, results suggest improved cessation cannot be 
attributed to progression to a superior SCM (e.g., varenicline) or number of SCMs used, although 
it would be prudent to attempt replication as SCM availability/use patterns change over time. 
The act of switching appeared to be driving better quit success, regardless of the SCMs smokers 
were switching to/from. Future studies could test this systematically through sequential, multiple 
assignment, randomized trial designs,27 with relapsers (i.e., treatment non-responders) assigned 
to the same or alternative SCM regime. Potential mechanisms could also be explored to delineate 
whether effects are due to reducing the difficulty of quitting (e.g., nicotine withdrawal, 
stress/negative affect) or enhancing treatment engagement (e.g., less treatment fatigue). 
 
Limitations 
First, only variability in the use of SCMs was examined. The degree to which these findings 
apply to behavioral treatments, or combined use of pharmacologic and behavioral strategies, is 
unknown. Second, quit success was based on self-reported abstinence without biochemical 
verification. Although this approach conforms to recommendations put forward by the Society 
for Research on Nicotine and Tobacco,28,29 there are numerous definitions of quit success and 
methods to validate smoking status. Third, characterization of SCMs used on QAs was based on 
the most recent QA prior to each assessment wave. Additional QAs may have occurred between 
waves, and may or may not have involved SCMs, but the current analyses are unable to account 
for potential QAs/SCMs. Finally, SCM use for each QA was examined, but not the dose or 
duration of each, which is an important limitation as proper dosing of SCMs is likely to be an 
important correlate of smoking abstinence.30,31 Adherence regimens vary across SCMs, which 
may influence perceptions of treatment burden/fatigue, noncompliance, and ultimately relapse.32 
Noncompliance is commonly observed,31 so perhaps switchers had better outcomes because they 
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moved to SCMs to which they could better adhere. Even with these limitations, this study 
provides the first real evidence to support a recommendation to encourage smokers who fail on 
one SCM (or combination) to switch to a different SCM (or combination) on a subsequent QA. 
 
CONCLUSIONS 
Future research should replicate findings, and expand upon the current study with greater 
precision by including more frequent assessments and examining variability in the use of both 
pharmacologic and behavioral treatments across QAs. Future studies should also examine a wide 
range of potential explanations for the observed effects to contribute toward a precision medicine 
approach. In addition to adherence issues noted above, some medications may be more effective 
for certain types of smokers. For example, pharmacogenomic studies suggest NRT may be better 
suited for smokers with genotypes associated with nicotine metabolism33 or reduced aversive 
responses to nicotine.34 Those without these genotypes may not find NRT effective, or may 
experience side effects that limit adherence. There is a need for future work to explore 
interactions between genetic and psychosocial predictors of switching, as well as potential order 
effects (e.g., SCMs trials). 
 
Findings from this study suggest a subset of smokers remain highly engaged in quitting despite a 
history of relapse, and are willing to use SCMs to aid future QAs. The finding that smokers can 
increase their odds of abstinence by varying their use of SCMs provides evidence to suggest 
smokers could be advised to try new quit methods. 
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Table 1. Sample Characteristics by Smoking Cessation Medication (SCM) Use Across Two Quit Attempts (QAs) 
  
 
SCM users during 1 QA SCM users during both QAs Significance tests 
Covariate Overal
l 
Non-
users 
Early 
users 
(prior QA) 
Later users 
(current 
QA) 
Repeaters 
(same 
SCM) 
Switchers 
(different 
SCM) 
Omnibus Repeater
s vs. all 
others 
Switchers 
vs. all 
others 
Repeater
s vs. 
switchers 
Total QA 
pairs 
(N=1,057) 
 45.3% 
(n=479) 
11.4% 
(n=120) 
18.4% 
(n=195) 
10.7% 
(n=113) 
14.2% 
(n=150) 
    
Country     
  
χ2=35.8*** χ2=9.8* χ2=8.9* χ2=4.5 
United 
Kingdom 
27.4% 54.1% 11.0% 17.2% 9.0% 8.6%     
Canada 23.1% 47.5% 11.9% 15.2% 12.3% 13.1%     
Australia 18.7% 34.3% 10.1% 20.7% 16.2% 18.7%     
U.S. 30.7% 42.5% 12.0% 20.6% 7.7% 17.2%     
Sex       χ2=11.5* χ2=0.6 χ2=2.1 χ2=0.1 
Female 61.3% 41.2% 12.0% 20.1% 11.4% 15.3%     
Male 38.7% 51.8% 10.3% 15.9% 9.5% 12.5%     
Age group 
(years) 
      χ2=13.3 χ2=0.7 χ2=3.7 χ2=1.1 
18-24 5.9% 56.5% 9.7% 11.3% 9.7% 12.9%     
25-39 22.5% 45.0% 11.8% 13.9% 11.3% 18.1%     
40-54 41.2% 44.1% 12.6% 20.2% 10.3% 12.6%     
55+ 30.5% 45.0% 9.6% 20.8% 10.9% 13.7%     
Majority/ 
Minority 
status 
      χ2=13.2** χ2=3.8 χ2=1.4 χ2=0.5 
Majority 88.5% 43.6% 11.9% 18.3% 11.4% 14.8%     
Minority 11.5% 58.2% 7.4% 19.7% 4.9% 9.8%     
Education       χ2=16.0* χ2=3.8 χ2=1.8 χ2=0.2 
Low 49.4% 43.1% 12.6% 22.2% 8.8% 13.2%     
Moderate 32.8% 47.3% 11.0% 15.3% 12.1% 14.4%     
High 17.8% 47.9% 8.5% 13.8% 13.3% 16.5%     
Income       χ2=10.0 χ2=2.5 χ2=2.4 χ2=3.1 
Low 33.3% 44.3% 11.1% 20.5% 10.2% 13.9%     
Moderate 32.5% 46.2% 11.0% 18.0% 9.3% 15.4%     
High 28.7% 43.2% 12.9% 17.8% 11.9% 14.2%     
Unknow
n 
5.5% 56.9% 6.9% 12.1% 15.5% 8.6%     
22 
Self-efficacy       χ2=26.48**
* 
χ2=0.3 χ2=4.1 χ2=2.1 
Low 48.4% 42.4% 10.5% 18.9% 11.1% 17.0%     
Moderate 33.4% 46.5% 11.9% 18.1% 10.2% 13.3%     
High 18.2% 51.0% 12.5% 17.7% 10.4% 8.3%     
Nicotine 
dependence 
(0-6), M(SE) 
2.5 
(1.5) 
2.1 (1.5) 2.7 (1.4) 2.9 (1.5) 2.8 (1.4) 3.1 (1.3) F2=18.8*** χ2=5.8* χ2=22.0**
* 
χ2=1.5 
Note: Boldface indicates statistical significance (*p<0.05; **p<0.01; ***p<0.001); 795 respondents contributed to 1,057 QAs. 
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Table 2. 1-month Point Prevalence Abstinence as a Function of Smoking Cessation Medication Use Across Quit Attempts   
Adjusted (N=795; Wave Pairs=1,057) 
  Model 1: Non-users as referent Model 2: Switchers as referent 
SCM use % Quit OR 95% CI p-value OR 95% CI p-value 
Lower Upper Lower Upper 
Non-users 15.9% ref - - - 0.48 0.30 0.76 0.002 
Early users 
(prior QA) 
16.6% 1.05 0.61 1.80 0.86 0.50 0.27 0.92 0.03 
Later users 
(current QA) 
20.0% 1.32 0.86 2.03 0.21 0.63 0.37 1.06 0.08 
Repeaters 12.4% 0.75 0.40 1.40 0.36 0.36 0.18 0.72 0.004 
Switchers 28.5 % 2.10 1.31 3.36 0.002 ref - - - 
Note: Boldface indicates statistical significance (*p<0.05). Adjusted models included: country, sex, age, majority/minority status, 
education, income, self-efficacy, and heaviness of smoking index. 
 
SCM, smoking cessation medication; QA, quit attempt 
 
24 
Table 3. Frequencies of Smoking Cessation Medications (SCMs) Used by Repeaters and Switchers 
SCM use Overall first 
QA (N=263) 
Overall 
second QA 
(N=263) 
Repeaters 
(N=113) 
Switchers first 
QA (N=150) 
Switchers 
second QA 
(N=150) 
Repeaters versus 
switchers second 
QA 
Specific SCM(s) used       
Patch 36.1% 25.9% 38.9% 34.0% 16.0% -22.9% 
Varenicline 23.2% 31.6% 30.1% 18.0% 32.7% 2.6% 
Bupropion 8.4% 4.2% 5.3% 10.7% 3.3% -2.0% 
Gum 8.4% 6.1% 8.0% 8.7% 4.7% -3.3% 
Patch and gum 6.8% 3.0% 3.5% 9.3% 2.7% -0.8% 
Lozenge 3.8% 4.2% 4.4% 3.3% 4.0% -0.4% 
Other prescription 1.5% 3.0% 0.9% 2.0% 4.7% 3.8% 
Gum and lozenge 1.5% 1.1% 0.0% 2.7% 2.0% 2.0% 
Patch and lozenge 1.5% 0.8% 0.9% 2.0% 0.7% -0.2% 
Other NRT 1.1% 1.9% 0.9% 1.3% 2.7% 1.8% 
Gum and Varenicline 1.1% 1.1% 0.9% 1.3% 1.3% 0.4% 
Patch and Bupropion 1.1% 1.5% 1.8% 0.7% 1.3% -0.5% 
Patch and other NRT 1.1% 3.8% 0.9% 1.3% 6.0% 5.1% 
Patch and tab 1.1% 1.5% 1.8% 0.7% 1.3% -0.5% 
Gum and other NRT 0.4% 1.1% 0.9% 0.0% 1.3% 0.4% 
Cumulative SCM(s) used       
Any NRT 66.5% 59.7% 63.7% 68.7% 56.7% -7.0% 
Any NRT combo 13.3% 13.7% 8.0% 17.3% 18.0% 10.0% 
Any Bupropion 9.9% 9.5% 7.1% 12.0% 11.3% 4.2% 
Any Varenicline 25.1% 38.0% 31.0% 20.7% 43.3% 12.3% 
Any prescription 49.4% 63.1% 57.5% 46.7% 67.3% 9.8% 
Note: 19 additional SCMs were used by <1% of the sample during either the first or second QA (tab, patch, and other prescription, patch and 
Varenicline, Varenicline and other prescription, patch and gum and other NRT, patch and gum and Bupropion and other prescription, Bupropion 
and other, prescription, gum and Bupropion, lozenge and Varenicline, other NRT and other prescription, other NRT and Varenicline, tab and 
Varenicline, other NRT and Varenicline and other prescription, patch and Bupropion and Varenicline, patch and gum and lozenge, patch and other 
NRT and Bupropion, patch and other NRT and Varenicline, patch and Bupropion and Varenicline and other prescription, patch and gum and 
Bupropion amd Varenicline 
 
QA, quit attempt; NRT, nicotine replacement therapy 
